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Abstract
Deep generative models such as generative adversarial networks, variational au-
toencoders, and autoregressive models are rapidly growing in popularity for the
discovery of new molecules and materials. In this work, we introduce MOlecular
SEtS (MOSES), a benchmarking platform to support research on machine learning
for drug discovery. MOSES implements several popular molecular generation
models and includes a set of metrics that evaluate the diversity and quality of
generated molecules. MOSES is meant to standardize the research on molecular
generation and facilitate the sharing and comparison of new models. Addition-
ally, we provide a large-scale comparison of existing state of the art models and
elaborate on current challenges for generative models that might prove fertile
ground for new research. Our platform and source code are freely available at
https://github.com/molecularsets/moses.
1 Introduction
Many challenges of the 21st century, from personalized healthcare to energy production and storage
[1], are linked by material discovery and development. The discovery of new molecules can bring
enormous societal and technological progress, potentially curing rare diseases and providing a
pathway for personalized precision medicine [2]; disruptive advances are likely to come from
unexplored regions of the set of all possible chemical compounds. But a complete exploration of
the huge space of potential chemicals is computationally intractable. It has been estimated that
the number of pharmacologically-sensible molecules is in the order of 1023 to 1080 compounds
[3, 4]. Furthermore, often this search space can be constrained based on known chemistry, patented
molecules, and desired qualities (e.g., solubility or toxicity). There have been many approaches
to mapping and mining the space of possible molecules, including high throughput screening,
combinatorial libraries, evolutionary algorithms, and other techniques [5–8]. The exponential growth
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Figure 1: Molecular Sets (MOSES) pipeline. The open-source library provides a dataset, baseline
models, and evaluation metrics.
of publicly available experimental data also increases popularity of machine learning applications in
bioinformatics [9, 10] for predicting pharmacological properties of drugs [11], biomarker development
[12–15], target identification [16], antibacterial drug discovery [17], and drug repurposing [18]. Deep
generative models were successfully validated in the applied task of generating DDR1 inhibitors
[19]—generated molecules showed nanomolar activity in the enzymatic assay and high efficacy in
the cell-based liver fibrosis model. The lead compound also exhibited favorable AMDE properties,
including PK profile in mice.
Over the last few years, advances in machine learning, and especially in deep learning, have driven the
design of new computational systems that improve with experience and are able to model increasingly
complex phenomena. One approach that has been proven fruitful for the modeling of the distribution
of molecular data has been deep generative models. Just as we can sample random numbers from a
random variable distribution, generative models learn to model a data distribution in a way amenable
for sampling new data points or conditioning over certain properties.
Deep generative models have shown remarkable results in a wide range of settings, from generating
synthetic images [20] and natural language texts [21], to the applications in biomedicine, including
the design of DNA sequences [22], and aging research[23]. One important field of application for
deep generative models lies in the inverse design of organic molecules [24]: for a given functionality
(solubility, ease of synthesis, toxicity or presence of particular molecular fragments, etc.) we wish
to find the perfect molecule that meets these requirements. The inverse design uses optimization,
sampling, and search methods to navigate the manifold of the functionality of chemical space. A
deep generative model fits these requirements since it learns the manifold of desired functionality and
allows to map this functionality back to the chemical space.
Part of the success of deep learning in different fields has been driven by ever-growing publicly
available datasets and standard benchmark sets. These sets serve as a common measuring stick for
newly developed models and optimization strategies; for example, when the field of computer vision
had more or less worked the classical MNIST dataset of handwritten digits into the ground [25],
larger and more complex datasets such as ImageNet [26] immediately took its place.
In the context of organic molecules, MoleculeNet [27] was introduced as a standardized benchmark
suite for discriminative tasks such as regression and classification, but at present, there is no counter-
part for generative models and generation tasks. We attribute this due to two main reasons: 1) lack
of a common benchmark set and 2) lack of metrics. Both reasons are hard to tackle since any given
molecular application will depend highly on the context. The molecules used for organic redox flow
batteries will differ quite significantly from molecules for Malaria transmission blocking. Even for a
common dataset, the desired qualities might differ greatly. For drug molecules, we sometimes seek a
diverse set of molecules to avoid an already patented chemical space, but it can also be advantageous
to find molecules that are quite similar in functionality and structure to a patented molecule while
being different enough.
Furthermore, it is not immediately clear how to compare deep generative models. There is no
clear-cut way to evaluate the quality of generated samples; in particular, the loss function of the
model itself is seldom a good choice for final evaluation. Often the real validation test for a candidate
sample requires experimental characterization either via multiple in-vitro experiments or a device
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prototype. Computational approaches for scoring molecules tend to suffer from a lack of accuracy
(e.g., target-ligand interaction) or are too time-consuming (e.g., simulating the electronic structure).
In this work, we aim to tackle both of these problems by providing a unified implementation of a
benchmark suite for molecular generation, including data preprocessing utilities, evaluation metrics,
and state of the art molecular generation models. While it is clear there can be no single solution to
cover all molecular applications, we hope that these contributions will serve as a clear and unified
testbed for current and future generative models. The proposed platform was discussed at multiple
conferences and workshops [28, 29], and it gains increasing attention of the research community.
In the following sections, we elaborate on the details of each of the features of MOSES and conclude
with evaluation results on a proposed dataset. We then discuss current challenges in the field of
molecular generation. We also highlight possible ideas for improvement in datasets outside of a
molecular biology context, alternative representations of molecules, and improvements in metrics for
the molecules. The pipeline of our framework is shown in Figure 1.
2 Dataset
Deep generative models require large datasets in order to learn patterns that can generalize and lead
to new molecules. While large datasets of molecules exist, there is no commonly accepted standard
dataset. The pharmaceutical industry has historically driven much of the large-scale development and
testing of molecular libraries via virtual screening and high-throughput screening. As Table 1 shows,
the largest datasets correspond to libraries utilized in medicinal chemistry.
Virtual screening libraries are often constructed from the application of common reactions to a set of
seed molecules; the reactions are such that their products are predictable and easily performed in a
laboratory setting while seed molecules are typically purchasable or easily synthesized or extracted
from natural products. Even though the coverage of reactions tends to be a small subset of all possible
reactions [30], the resulting combinations can lead to virtual libraries on the order of 1014 − 1018
compounds[31]. Large datasets with experimentally characterized labeled data are quite valuable for
constructing accurate models and libraries, so these tend to be closed-source and company-owned.
Most current molecular generation applications utilize a subset of ZINC or ChEMBL molecules. For
this purpose, we propose a biological molecule benchmark set refined from the ZINC database.
The set is based on the ZINC Clean Leads collection. It contains 4,591,276 molecules with molecular
weight in the range from 250 to 350 Daltons, a number of rotatable bonds not greater than 7, and
XlogP less than or equal to 3.5. We removed molecules containing charged atoms, atoms besides
C, N, S, O, F, Cl, Br, H, or cycles longer than 8 atoms. The molecules were filtered via medicinal
chemistry filters (MCFs) and PAINS filters [32].
Medicinal chemistry filters are used to discard compounds containing so-called “structural alerts”.
Molecules containing such moieties either bear unstable or reactive groups or undergo biotransforma-
tions resulting in the formation of toxic metabolites or intermediates. Herein, we present a list of
routine MCFs for the rational pre-selection of compounds more appropriate for modern drug design
and development. These include some electrophilic alkylating groups, such as Michael acceptors
(MCF1-3), alkyl halides (MCF4), epoxide (MCF5), isocyanate (MCF6), aldehyde (MCF7), imine
(Schiff base, MCF8), aziridine (MCF9) which are very liable for nucleophilic attack, e.g. by serine,
lysine or amino group of cysteine. In many cases, it leads to unselective protein and/or DNA damage.
Metabolism of hydrazine (MCF10) furnishes diazene intermediates (MCF11), which are also alky-
lating warheads. Monosubstituted furans (MCF12) and thiophenes (MCF13) are transformed into
reactive intermediates via epoxidation. Their active metabolites irreversibly bind nucleophilic groups
and modify proteins. Electrophilic aromatics (e.g. halopyridine, MCF14), oxidized anilines (MCF15)
and disulfides (MCF16) are also highly reactive. In vivo, alkylators are trapped and inactivated by
the thiol group of glutathione, which is a key natural antioxidant. Azides (MCF17) are highly toxic;
compounds containing this functional group particularly cause genotoxicity. Aminals (MCF18) and
acetals (MCF19) are frequently unstable and inappropriate in generated structures. In addition, virtual
structures containing a large number of halogens (MCF20-22) should be excluded due to increased
molecular weight and lipophilicity (insufficient solubility for oral administration), metabolic stability,
and toxicity. The detailed mechanism of toxicity for structure alerts mentioned above has been
comprehensively described in [33, 34].
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Table 1: Datasets for generation tasks.
Dataset Size Purpose
ZINC [35, 36] 980M Commercially available compounds for virtual screening
ChEMBL [37] 2M A manually curated database of bioactive drug-like molecules
SureChEMBL [38] 17M Named compounds from chemical patents
eMolecules 18M Purchasable molecules
SuperNatural [39] 330k Natural product molecules
DrugBank 10.5k FDA approved drugs, experimental drugs, drugs available worldwide
The final dataset contains 1,936,962 molecular structures. For experiments, we also provide a training,
test and scaffold test sets. The scaffold test set contains unique Bemis-Murcko scaffolds [40] that
were not present in the training and test sets. We use this set to assess how well the model can
generate previously unobserved scaffolds.
3 Representations
Before training a generative or predictive model on molecular data, one has to represent compounds
in a machine learning-friendly way. For generative tasks, we often would like to have a one-to-one
mapping between the molecule and its representation to do a quick search in a lookup table, perform
reconstruction, or sample new molecules (see example in Figure 2). For the generative models
considered in this work, we have focused on two primary forms of representation: sequences of
tokens via SMILES [41, 42] and molecular graphs. Both representations rely on empirical principles
of bonding, and a molecule is interpreted as an undirected graph where each atom is a node and
the bonds are the edges. To reduce complexity, hydrogen atoms are treated implicitly because they
are deduced from standard chemistry valence rules. A challenge when dealing with graphs is the
graph isomorphism problem: without an explicit ordering of nodes, two graphs can map to the same
structure and finding out whether they are equivalent is computationally demanding. This can be used
for data augmentation purposes; but conversely, it has been argued that this representation degeneracy
introduces noise to a model [43]. In this section, we expand on these two representations and also
elaborate on other alternatives that might be used for generative models.
Figure 2: Different representations of a vanillin molecule.
SMILES. Any graph can be transformed into a sequence of tokens by traversing its spanning tree
and collecting all visited edges and nodes as tokens. For molecules, the Simplified Molecular Input
Line System, or SMILES, defines grammar and syntax rules that are widely adopted in the chemistry
community. In order to remove ambiguity, SMILES supports a canonical ordering (canonical
SMILES) [44]. Additionally, SMILES can also encode the stereochemistry by specifying special
tokens for chirality (isomeric SMILES). A non-standard specification can also be adapted to include
specific types of bonds, fragments, etc.
Much of the popularity behind SMILES in molecular generative models [45–53] has been due to the
fast adaptation of sequence modeling tools such as recurrent neural networks, attention mechanisms,
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and dilated convolutions, among others, to the text nature of SMILES. However, in a string format,
we cannot preserve locality of atoms, and some atoms that are adjacent in the molecular graphs can
appear in distant positions in a string. Also, not every string with SMILES tokens is semantically
correct, i.e., represents a valid molecule, so a neural network has to track distant relationships in
SMILES, which leads to a lower number of valid strings. Some methods try to incorporate SMILES
syntax into a network architecture to increase the fraction of valid molecules [54, 55]. There is also an
International Chemical Identifier (InChI) [56] format, which is a more verbose string representation,
explicitly specifying a chemical formula, charges, hydrogens, and isotopes.
Molecular graphs. In a machine learning context, graphs are normally represented via sparse
adjacency matrices with values corresponding to the presence or absence of edges between vertices.
These matrices are augmented with node and edge feature vectors since nodes and edges in molecular
graphs are likely to include physical properties related to the atoms and bonds. Often these are
represented as sparse tensors [57].
There are multiple ways of processing and taking into account information defined on a graph, and so
several approaches have been proposed such as Graph Convolutional Networks [58], Weave Networks
[27], and Message Passing Networks [59]. The molecular graph can be represented implicitly as an
adjacency matrix with different atoms encoded along certain dimensions of the tensor; this approach
has been successfully used in the MolGAN model [60] for the QM9 dataset [61]. Another approach
for treating graphs was introduced with the Junction Tree VAE model [62], which, instead of modeling
a molecular graph as an atom-wise graph, interprets each molecule as a composition of subgraphs
chosen from a vocabulary of fragments.
3D structure and alternative representations. For a long time, one of the most common represen-
tations for molecular structures has been a fingerprint, a fixed-length vector indicating the presence or
absence of a chemical environment [63, 64]. Fingerprints are not typically invertible but can be used
for fast screening by similarity to available in-house compounds. Kadurin et al. [52] implemented
VAE and AAE models based on Molecular Access System (MACCS) fingerprints to screen for novel
compounds with the desired effect. Polykovskiy et al. [65] proposed a generative model for creating
molecular structures for a given fingerprint, training a simple generator on fingerprints, and then
transforming them into SMILES with a separate model. However, fingerprints often lack biological
relevance and do not fit into the process of designing novel compounds.
One shortcoming of using molecular graphs and SMILES to model chemical and physical phenomena
is that they represent a description of molecules on the level of atoms. A complete description
of a molecule will require to take into account their 3D coordinates, symmetries with respect to
the Schrödinger equation, and possibly its electrons. This is a current open research problem, and
therefore we would like to draw attention to other works that involve alternative representations for
molecules and could be potentially used or expanded for generative models.
One promising direction lies in a wavefunction or electronic density representation of molecules;
these should, in principle, contain all information needed for an exact description of the physics
and chemistry of a molecule. An initial approximation was introduced with the help of invertible
hamiltonians via Coulomb matrices [66] that contain pairwise Coulomb interactions between atoms.
Their generalization can be seen as tensors that encode multiple symmetries and physical properties
of atoms [67]. The use of electronic densities has also been explored for prediction [68].
Another representation has relied on position molecules within a 3D grid space, often with channels
for different types of atoms, where a voxel is non-zero when it contains an atom. This representation
is quite flexible since it can also incorporate information about the binding position in an active
site of a protein [69, 70]. One major challenge of this representation is sparsity; for this purpose,
Kuzminykh et al. [71] proposed an invertible smoothing transformation to reduce sparsity in the
3D space. Building generative models on 3D representations remains an open problem. One of the
current approaches that allows to work directly in the 3D space is providing 3D coordinates to graph
nodes or SMILES atoms.
4 Metrics
Generative models are supposed to produce a wide variety of different samples. Therefore, to evaluate
generative models one has to compare sets of generated molecules, looking for coverage of the ground
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truth, diversity among generated objects, and similarity between various statistical properties of the
generated set and the reference set. To this purpose, we have utilized five metrics that can be used
to compare a generated set of molecules G and a reference set of molecules R: fragment similarity,
scaffold similarity, nearest neighbor similarity (based on Morgan structural fingerprints and Gobby
2D topological fingerprints), internal diversity, and Fréchet ChemNet Distance. We also present a set
of auxiliary metrics useful for the drug design process but could be extended for other applications.
Fragment similarity (Frag) is defined as the cosine distance between vectors of fragment frequen-
cies. For a set of molecules G, its fragment frequency vector fG has a size equal to the size of the
vocabulary of all chemical fragments in the dataset, and elements of fG represent frequencies with
which the corresponding fragments appear in G. The distance is then defined as
Frag(G,R) = 1− cos(fG, fR), (1)
where molecules in both G and R are fragmented using the BRICS algorithm [72] implemented
in RDKit [73]. This metric shows the similarity of two sets of molecules at the level of chemical
fragments.
Scaffold similarity (Scaff) is calculated in a similar way, as cosine similarity between the vectors
sG and sR that represent frequencies of scaffolds in sets of molecules G and R:
Scaff(G,R) = 1− cos(sG, sR), (2)
Scaffolds are derived from the molecules by removing side chain atoms using the Bemis–Murcko
algorithm [40], also implemented in RDKit [73]. The purpose of this metric is to show how similar are
the scaffolds in generated and reference datasets. Note that in both fragment and scaffold similarity
the comparison is at a substructure level but not molecule level, i.e. it is possible to have a distance of
0 (identical) with two different sets of molecules, as long as their substructure counts are the same.
Nearest neighbor similarity (SNN) is the average Tanimoto similarity T (mG,mR) (also known
as the Jaccard index) between a molecule mG from the generated set G and its nearest neighbor
molecule mR in the reference dataset R:
SNN(G,R) =
1
|G|
∑
mG∈G
max
mR∈R
T (mG,mR), (3)
wheremR andmG are some representations of the molecules as bit strings (fingerprints); the resulting
similarity metric shows how generated molecules are similar to reference molecules in terms of the
chemical structures that are encoded in these fingerprints. In this work, we used standard Morgan
[74] fingerprints with radius 2 and 1024 bits. This representation is useful for a general analysis of
the chemical space considering the constant search for novel scaffolds and chemotypes which is an
essential part of the modern drug discovery process.
In general, molecules with similar chemical structures tend to possess the same biological response,
there are more common features called pharmacophores that are responsible for biological activity.
It has been shown that structurally diverse ligands with common pharmacophore hypothesis can
bind to the same receptor site [75]. Therefore, nearest neighbor similarity calculated using 2D
pharmacophore fingerprints [64] can be beneficial when comparing two sets of molecules with
regards to the biological targets they can bind to.
Internal diversity (IntDivp) [76] assesses the chemical diversity within the generated set of
molecules G.
IntDivp(G) = 1− p
√
1
|G|2
∑
m1,m2∈G
T (m1,m2)p. (4)
While SNN measures the dissimilarity to the reference dataset (external diversity), the internal
diversity metric evaluates the generated molecules. This metric detects a common failure case of
generative models—mode collapse. With mode collapse, the model produces a limited variety of
samples, ignoring some areas of chemical space. A higher value of the metric corresponds to higher
diversity in the generated set. In the experiments, we report IntDiv1(G) and IntDiv2(G).
Fréchet ChemNet Distance (FCD) [77] is calculated using the penultimate layer of the deep neural
network ChemNet trained to predict the biological activities of drugs. The activations represent both
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chemical and biological properties of the compounds. For two sets of molecules G and R, FCD is
defined as
FCD(G,R) = ‖µG − µR‖2 + Tr
(
ΣG + ΣR − 2(ΣGΣR)1/2
)
, (5)
where µG, µR are mean vectors and ΣG, ΣR are covariance matrices of the activations on the
penultimate layer of ChemNet on the sets G and R respectively.
We believe that these five metrics provide good coverage of various desirable properties of a set of
generated molecules, and we propose to use them as standard metrics for the comparison of different
generative models for molecular fingerprints and structures.
Auxiliary Metrics. For evaluation purposes, we have also included utilities for computing auxiliary
metrics that represent qualities that are commonly used for small molecule drug discovery.
• Molecular weight (MW): the sum of atomic weights in a molecule.
• LogP: the water-octanol partition coefficient, a property that measures how likely a molecule
is able to mix with water. Computed via RDKit’s Crippen [78] function.
• Synthetic Accessibility Score (SA): a heuristic estimate of how hard (10) or how easy
(1) it is to synthesize a given molecule. SAscore is based on a combination of fragment
contributions and a complexity penalty [79].
• Quantitative Estimation of Drug-likeness (QED): a 0 to 1 float value estimating how
likely a molecule is a viable candidate for a drug. QED is meant to capture the abstract
notion of aesthetics in medicinal chemistry [80].
• Natural Product-likeness Score (NP): a numerical estimate that can be used to determine
if a molecule is likely to be a natural product (0 . . . 5), a drug molecule (−3 . . . 3) or a
synthetic product (−5 . . . 0). This score is calculated from several substructure descriptors
and comparing them to the properties of other distributions of molecules [81].
To quantitatively compare the distributions in the generated and test sets, we use the Fréchet distance.
Alternatively, distributions of molecules can be compared in a simplified manner by looking at the
mean and variance of properties.
5 Models
In the current version of MOSES, we implemented several deep learning models that cover different
approaches to molecule generation problem such as language models modeled as character-level
recurrent neural networks (CharRNN) [46, 77], Variational Autoencoders (VAE) [82–84], Adver-
sarial Autoencoders (AAE) [83, 65], Junction Tree Variational Autoencoders (JT-VAE) [62], and
LatentGAN [85]. These baseline models are trained in an unsupervised or semi-supervised fashion.
Most models are based on the SMILES representation of a molecule and as such, will typically
incorporate sequence modeling tools such as recurrent neural networks (RNN) with different types of
cells. There are many new models coming out dealing with other representations of molecules such
as the JT-VAE which works with molecular graphs as tensors. Although more models will be added,
we believe the current coverage in the collection is sufficient for good comparison of any arbitrary
new model.
Model comparison can be challenging since different training parameters (number of epochs, batch
size, learning rate, initial state, optimizer) and architecture hyperparameters (hidden layer dimension,
number of layers, etc.) can significantly alter their performance. For each model, we attempted to
preserve its original architecture as published and tweaked hyperparameters to improve performance.
We used random search over multiple architectures for every model and selected the architecture
that produced the lowest FCD. All models are implemented with Python 3 utilizing the PyTorch [86]
framework. Next, we briefly introduce these models.
Character-level recurrent neural networks (CharRNN) [46] treats the task of generating SMILES
as a language model attempting to learn the statistical structure of SMILES syntax by training it on
a large corpus of SMILES (Figure 3). Model parameters are optimized using maximum likelihood
estimation (MLE). CharRNN is implemented using Long Short-Term Memory [87] RNN cells
stacked into 3 layers with hidden dimension 768 each. We used a dropout [88] layer with dropout
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rate 0.2. Softmax is utilized as an output layer. Training is done with a batch size of 64, using the
Adam [89] optimizer for 80 epochs with a learning rate of 10−3 halved after each 10 epochs.
…
Figure 3: CharRNN model. A model is trained by maximizing the likelihood of known molecules.
Variational autoencoder (VAE) is a framework for training two neural networks—an encoder and a
decoder—to learn a mapping from high-dimensional data representation into a lower-dimensional
space and back. The lower-dimensional space is called the latent space, which is often a continuous
vector space with normally distributed latent representation. VAE parameters are optimized to encode
and decode data by minimizing the reconstruction loss while also minimizing a KL-divergence
term arising from the variational approximation that can loosely be interpreted as a regularization
term (Figure 4). Since molecules are discrete objects, properly trained VAE defines an invertible
continuous representation of a molecule.
A VAE-based architecture for the molecular generation was initially proposed by Gómez-Bombarelli
et al. [82], and alternative architectures have been proposed by Kadurin et al. [83] and Blaschke et al.
[84]. We combine aspects from both implementations in MOSES. Utilizing a bidirectional [90] Gated
Recurrent Unit (GRU) [91] with a linear output layer as an encoder. The decoder is a 3-layer GRU of
512 hidden dimensions with intermediate dropout layers with dropout probability 0.2. Training is
done with a batch size of 128, utilizing a gradient clipping of 50, KL-term weight linearly increased
from 0 to 1 during training. We optimized the model using Adam optimizer with a learning rate of
3 · 10−4. We trained the model for 100 epochs.
Figure 4: Autoencoder-based models. VAE/AAE forms a specific distribution in the latent space.
Adversarial Autoencoders (AAE) [92] combine the idea of VAE with that of adversarial training as
found in GAN. One of the main drawbacks of VAE is the KL divergence term that has a closed-form
analytical solution only for a handful of distributions. In AAE, the KL divergence term is avoided by
training a discriminator network to predict whether a given sample came from the latent space of
the AE or from a prior distribution. Parameters are optimized to minimize the reconstruction loss
and to minimize the discriminator loss. Kadurin et al. [83] applied AAE architecture to the drug
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generation task. The model consists of an encoder with a 1-layer bidirectional LSTM with 512 hidden
dimensions, a decoder with a 2-layer LSTM with 512 hidden dimensions and a shared embedding of
size 128. The discriminator network is a 2-layer fully connected neural network with 640 and 256
nodes respectively with exponential linear unit (ELU) [93] activation function [94]. Training was
done with a batch size of 512, with the Adam optimizer using a learning rate of 10−3 for 120 epochs.
We halved the learning rate after each 20 epochs.
Junction Tree VAE (JT-VAE) [95] is one of the first deep generative models that explicitly made use
of a graph representation of molecules. The JT-VAE generates molecules in two phases by exploiting
valid subgraphs as components. In the first phase, it generates a tree-structured object (a junction tree)
whose role is to represent the scaffold of subgraph components and their coarse relative arrangements.
The components are valid chemical substructures automatically extracted from the training set using
tree decomposition and are then used as building blocks. In the second phase, the subgraphs (nodes
of the tree) are assembled together into a coherent molecular graph. We report the experimental
results from the official JT-VAE repository [96].
Latent Vector Based Generative Adversarial Network (LatentGAN) [85] combines autoencoder
and GAN architectures. The authors pretrained and autoencoder on MOSES training set to map
SMILES structures to latent vectors. They then trained a Wasserstein GAN with gradient penalty
(WGAN-GP) [97] on latent codes of an autoencoder (Figure 5). The autoencoder architecture is
a heteroencoder [98] containing a two-layer bidirectional encoder with 512 LSTM units per layer.
Authors added a Gaussian noise with a zero mean standard deviation of 0.1 to the latent codes,
resembling VAE with a fixed variance of proposal distributions. The LSTM decoder had 4 layers.
The neural network was trained on pairs of randomly chosen non-canonical SMILES strings [99].
The autoencoder network was trained for 100 epochs with a batch size of 128 sequences, using Adam
optimizer with a learning rate 10−3 for first 50 epochs and with an exponential learning rate decay
reaching a value of 10−6 in the final epoch. LatentGAN uses Wasserstein GAN with gradient penalty
(WGAN-GP) [97] with a fully connected discriminator with 3 layers of which the first two used the
leaky ReLU activation function, and the last layer no activation function. The generator consisted
of five fully connected layers with batch normalization and leaky ReLU activation. The GAN was
trained for 2000 epochs using a learning rate of 2 · 10−4 with Adam parameters β1 = 0.5, β2 = 0.9.
Figure 5: LatentGAN model. A model combines an autoencoder and generative adversarial networks.
6 Results
We trained baseline models on the proposed dataset and tuned hyperparameters independently
to achieve minimal FCD score on the test dataset. In Table 2 and Table 3, we provide metrics
implemented within the MOSES platform. The most up-to-date version of the comparison table
can be found at https://github.com/molecularsets/moses. According to the experiments,
CharRNN outperforms other architectures on the Fréchet ChemNet distance metric (FCD), suggesting
the CharRNN describes the chemical space better than other models. AAE is better in discovering
novel scaffolds as suggested by Scaff/TestSF metric, while LatentGAN produces the highest rate of
novel compounds.
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Table 2: Performance metrics for baseline models: fraction of valid molecules, fraction of unique
molecules from 1,000 and 10,000 molecules, internal diversity, fraction of molecules passing filters
(MCF, PAINS, ring sizes, charges, atom types).
Model Valid (↑) Unique@1k (↑) Unique@10k (↑) IntDiv (↑) IntDiv2 (↑) Filters (↑)
Train 1.0 1.0 1.0 0.857 0.851 1.0
AAE 0.937 1.0 0.997 0.856 0.85 0.996
(± 0.034) (± 0.0) (± 0.002) (± 0.003) (± 0.003) (± 0.001)
CharRNN 0.975 1.0 0.999 0.856 0.85 0.994
(± 0.026) (± 0.0) (± 0.0) (± 0.0) (± 0.0) (± 0.003)
JTN-VAE 1.0 1.0 0.999 0.851 0.845 0.978
LatentGAN 0.899 1.0 0.998 0.856 0.85 0.969
VAE 0.977 1.0 0.998 0.856 0.85 0.997
(± 0.001) (± 0.0) (± 0.001) (± 0.0) (± 0.0) (± 0.0)
Table 3: Scaffold split metrics for baseline models: Fréchet ChemNet Distance (FCD), Similarity to
the nearest neighbour (SNN), Fragment similarity (Frag), Scaffold similarity (Scaff), Novelty.
Model FCD (↓) SNN (↑) Frag (↑) Scaf (↑) Novelty (↑)Test TestSF Test TestSF Test TestSF Test TestSF
Train 0.008 0.476 0.642 0.586 1.0 0.999 0.991 0.0 0.0
AAE 0.556 1.057 0.608 0.568 0.991 0.99 0.902 0.079 0.793
(± 0.203) (± 0.237) (± 0.004) (± 0.005) (± 0.005) (± 0.004) (± 0.037) (± 0.009) (± 0.028)
CharRNN 0.073 0.52 0.601 0.565 1.0 0.998 0.924 0.11 0.842
(± 0.025) (± 0.038) (± 0.021) (± 0.014) (± 0.0) (± 0.0) (± 0.006) (± 0.008) (± 0.051)
JTN-VAE 0.422 0.996 0.556 0.527 0.996 0.995 0.892 0.1 0.915
LatentGAN 0.275 0.777 0.54 0.514 0.999 0.997 0.889 0.107 0.952
VAE 0.099 0.567 0.626 0.578 0.999 0.998 0.939 0.059 0.695
(± 0.013) (± 0.034) (± 0.0) (± 0.001) (± 0.0) (± 0.0) (± 0.002) (± 0.01) (± 0.007)
According to the results, after proper hyperparameter tuning, the majority of generated molecules are
novel, valid, diverse molecules passing predefined filters. This suggests that most models are capable
of covering the space and discovering novel compounds. According to Scaf/TestSF metric, most
models produce molecules with novel scaffolds not seen during training.
In Figure 6, we compare the distributions of chemical properties in generated and reference sets.
Note that most models match the shape of the distribution. The weight descriptor is bounded in the
training set, but all models generate molecules slightly outside the training bounds.
7 Discussion
With MOSES, we have designed a molecular generation benchmark platform that combines several
existing state-of-the-art baseline models and several evaluation metrics. This platform should allow for
a fair and comprehensive comparison of new generative models. Providing a one-size-fits-all solution
for a given molecular application is not possible since the constraints, chemistry, and properties of
interest are highly varied and very specific for a given context. We design MOSES as the first baseline
of comparison, providing metrics that allow taking into account several perspectives relevant to
molecular generation. For future work on this project, we will keep extending the MOSES repository
with new baseline models, updated evaluation tables, as well as incorporating new evaluation metrics.
We also wish to highlight and re-emphasize several research directions and challenges that future
generative models and efforts should tackle.
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Figure 6: Distribution of chemical properties for MOSES dataset and sets of generated molecules. In
brackets—Fréchet distance to MOSES dataset.
• Non-atom centric representations of molecules. Most generative models have focused on
the usage of molecular graph either explicitly or as SMILES. To be able to describe more
accurately and completely molecular processes, we might need representations that include
information related to electrons or 3D structure of a molecule.
• Hierarchical representations of molecules. As noted with JT-VAE, a hierarchical model
might be able to leverage structure at different scales (atoms, fragments, etc.). This might
prove important towards moving from small molecules to proteins, where the number of
atoms can be on the order of thousands. Structured representations might benefit from
reduced complexity in processing time but also for prediction.
• More general metrics. Current auxiliary metrics have been developed around heuristics and
rules of medicinal chemistry, often validated with small datasets due to the lack of publicly
available datasets. To build better generative models, we need more accurate metrics that go
beyond just medicinal chemistry. Measuring the synthetic accessibility, and cost of synthesis
of a molecule, incorporating reaction path between commercially available reactants and
natural products is important [100], as well as measuring reliably solubility and miscibility
between materials, in a variety of molecules environments [101].
We hope this work enables future researchers interested in tackling molecular and material challenges.
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